Replication competent adenoviral vectors

Patent metadata

Field	Value
Publication number	US-11268108-B2
Application number	US-201816756376-A
Country	US
Kind code	B2
Filing date	Oct 16, 2018
Priority date	Oct 16, 2017
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.

First claim

What is claimed is:

1. A replication competent simian adenoviral vector comprising an expression cassette which comprises a promoter and a transgene, wherein the expression cassette is inserted in the E3 region, the HE1 site or the HE2 site of the vector and wherein the simian is a chimpanzee or a bonobo.

2. The replication competent adenoviral vector of claim 1 , wherein the vector comprises a nucleotide sequence encoding one or more of a chimpanzee or bonobo adenoviral fiber polypeptide and a chimpanzee or bonobo adenoviral E4 region.

3. The replication competent simian adenoviral vector of claim 1 , wherein the vector is an adenovirus with a low seroprevalence in humans.

4. A replication competent chimpanzee adenoviral vector of claim 1 , wherein the vector is ChAd155.

5. A replication competent chimpanzee adenoviral vector of claim 1 , wherein the vector is ChAd83.

6. The replication competent simian adenoviral vector of claim 1 , wherein the promoter is chosen from a CASI promoter and an enhanced cytomegalovirus promoter.

7. The replication competent simian adenoviral vector of claim 6 , wherein the promoter is a CASI promoter.

8. The replication competent simian adenoviral vector of claim 6 , wherein the promoter is an enhanced cytomegalovirus promoter.

9. The replication competent simian adenoviral vector of claim 1 , wherein the expression cassette further comprises a posttranscriptional regulatory element.

10. The replication competent simian adenoviral vector of claim 9 , wherein the posttranscriptional regulatory element is a Woodchuck Hepatitis Postranscriptional Regulatory Element.

11. The replication competent simian adenoviral vector of claim 1 , wherein the transgene is an antigen.

12. The replication competent simian adenoviral vector of claim 11 , wherein the antigen is chosen from a rabies virus antigen, a respiratory syncytial virus antigen, a human immunodeficiency virus antigen, a tuberculosis antigen, a malaria antigen, a hepatitis C virus antigen, a Chikungunya antigen and a hepatitis B virus antigen.

13. The replication competent simian adenoviral vector of claim 1 , wherein the expression cassette is inserted in the E3 region.

14. The replication competent simian adenoviral vector of claim 1 , wherein the expression cassette is inserted in the HE1 site.

15. The replication competent simian adenoviral vector of claim 1 , wherein the expression cassette is inserted in the HE2 site.

16. The replication competent simian adenoviral vector of claim 1 , wherein the vector is administered by intramuscular injection.

17. The replication competent simian adenoviral vector of claim 1 , wherein the vector is administered orally.

18. A method of using the replication competent simian adenoviral vector of claim 1 to induce an immune response against a disease caused by a pathogen in a subject in need thereof.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Ammendola Virginia
• Colloca Stefano
• Vitelli Alessandra

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P31/20

  for DNA viruses · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title